Analysts Set Victrex plc (VCT) Target Price at $2,601.67
Victrex plc (LON:VCT) has earned an average rating of “Hold” from the thirteen research firms that are currently covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is GBX 2,526.11 ($33.01).
A number of brokerages recently issued reports on VCT. Morgan Stanley downgraded Victrex to an “underweight” rating and lowered their price target for the stock from GBX 2,500 ($32.67) to GBX 2,300 ($30.05) in a research report on Friday. Peel Hunt restated an “add” rating on shares of Victrex in a research report on Wednesday, July 25th. UBS Group restated a “buy” rating and issued a GBX 3,600 ($47.04) price target (up from GBX 3,300 ($43.12)) on shares of Victrex in a research report on Thursday, October 4th. Citigroup restated a “neutral” rating on shares of Victrex in a research report on Tuesday, July 17th. Finally, Barclays restated an “underweight” rating and issued a GBX 2,380 ($31.10) price target (up from GBX 2,300 ($30.05)) on shares of Victrex in a research report on Tuesday, July 24th.
In other Victrex news, insider Jakob Sigurdsson bought 3,250 shares of Victrex stock in a transaction on Wednesday, July 25th. The shares were acquired at an average price of GBX 3,072 ($40.14) per share, for a total transaction of £99,840 ($130,458.64). Over the last 90 days, insiders purchased 3,262 shares of company stock valued at $10,021,700.
Victrex plc, through its subsidiaries, manufactures and sells polymers worldwide. It operates through two segments, Victrex Polymer Solutions and Invibio Biomaterial Solutions. The company offers VICTREX PEEK polymer materials; and biomaterial solutions for use in spine, dental, trauma, knee, cardiovascular, and orthopedic applications.
Recommended Story: How are Outstanding Shares Different from Authorized Shares?
Receive News & Ratings for Victrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Victrex and related companies with MarketBeat.com's FREE daily email newsletter.